Navigation Links
Covance Central Laboratory Services Again Ranks #1 in Global Investigator Satisfaction Survey
Date:7/29/2013

PRINCETON, N.J., July 29, 2013 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) today announced that its central laboratory services once again ranked first in an independent global survey of physician investigators participating in clinical trials.  Forty-seven percent of the study participants named Covance's central laboratory services as their "most preferred" central laboratory, with investigators citing Covance more than twice as often as the nearest competitor.  Investigators also reported having the "best overall relationship" with Covance, rating it 8.4 on a scale of 1 to 10.

Survey results underscore the growing importance of the selection of a preferred central laboratory because of its direct connection to investigators' satisfaction and their willingness to work with sponsors in the future.  In addition, most physicians who want to learn about being a clinical trial investigator talk first to other doctors involved in clinical trials.

"This study demonstrates that investigators around the world continue to recognize and value Covance's services and benefit from our decades of experience and extensive testing capabilities," said Jon Koch, Corporate Vice President and Global General Manager, Central Laboratory Services.  "Our ability to deliver central laboratory services on target and on time, coupled with our commitment to meeting the evolving needs of clients and investigators, is what makes Covance a leader in providing drug development services and helps our clients bring medicines to market faster."

The report shows a clear link between overall investigator satisfaction and sponsors' choice of central laboratory, with 100 percent of respondents reporting they were satisfied when pharmaceutical sponsors select the investigators' preferred central laboratory.  When pharmaceutical sponsors select the investigators' least preferred central laboratory, satisfaction drops significantly.  Respondents cited central laboratory preference as a key driver of satisfaction with the pharmaceutical sponsor as well, with 91 percent of investigators stating that they are more satisfied and willing to work with a sponsor on trials when sponsors have selected investigators' preferred central laboratory.  Ninety-eight percent of investigators indicate the central laboratory selected by the sponsor impacts their success (and that of their staff), their day-to-day activities, and their willingness to work with a particular sponsor on future studies.

Effective communication, a laboratory's reputation for reliability and quality, and easy-to-use collection kits are among the factors that lead to a strong relationship between investigators and a central laboratory, the report showed.  Respondents ranked Covance first in all of the key performance metrics, such as customer service, reliability, and timely and accurate reporting.

Covance, the largest and most experienced provider of clinical trial central laboratory services in the world, has five dedicated laboratories in the United States, Switzerland, Singapore, China, and Japan.  In the past five years, Covance central laboratories have conducted more than 214 million laboratory tests for more than 4,200 clinical trial protocols in approximately 100 countries, working with more than 125,000 investigator sites.

The "Clinical Trial Investigator Satisfaction and Central Laboratory Performance" survey, conducted in June and July by the Life Science Strategy Group, questioned physicians actively participating in pharmaceutical industry-sponsored clinical trials as investigators.  Participants were prescreened to ensure a high level of involvement and/or key decision-making authority for their investigative site.  All global geographies and practice settings were represented, as were more than 20 medical specialties.  The mean experience level in a clinical trial setting was 12.7 years.  The study, based on a survey of 258 clinical trial investigators globally, is an update of a similar study Life Science Strategy Group conducted in 2011.

To learn more about the study or to download sample pages from the report, visit www.lifesciencestrategy.com.

About Covance Inc.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $2 billion, global operations in more than 30 countries, and more than 12,000 employees worldwide.  Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Forward-Looking Statements
Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  All such forward-looking statements are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.  These risks and uncertainties include, without limitation, factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.  The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.


'/>"/>
SOURCE Covance Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Covance To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
2. Covance Reports First Quarter Net Revenue Growth Of 9.3% To $580 Million, Pro Forma EPS Of $0.75 And Adjusted Net Orders Of $716 Million
3. Covance Expands Singapore Central Laboratory by 50 Percent to Meet Clients Increased Asia Pacific Focus
4. Covance Inc. Invites You to Join the Webcast of Its First Quarter 2013 Financial Results Conference Call
5. Covance To Present At The Citi 2013 Global Healthcare Conference
6. Covance To Present At The Leerink Swann Global Healthcare Conference
7. Covance Reports Fourth Quarter Pro Forma Net Revenue Of $561 Million, Pro Forma EPS Of $0.73 And Adjusted Net Orders Of $769 Million
8. Covance To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
9. Covance Reports Third Quarter Pro Forma Net Revenue Of $542 Million, Pro Forma EPS Of $0.72 And Adjusted Net Orders Of $701 Million
10. Covance to Present at the Morgan Stanley Global Healthcare Conference
11. Covance Reports Second Quarter Pro Forma Net Revenue Of $538 Million, Pro Forma EPS Of $0.65 And Adjusted Net Orders Of $701 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 2017  Mirabilis Medical, a Seattle ... non-invasive surgery, announced today CE Mark authorization for ... uterine fibroids throughout the European Union.  The company ... the US Food and Drug Administration to begin ... the United States.  The Mirabilis System combines high-speed ...
(Date:3/24/2017)... and GENEVA , March 24, 2017 ... Tuberculosis Day revitalizes efforts to develop sutezolid as effective ... World Tuberculosis Day, TB Alliance and the Medicines Patent ... development of sutezolid, an antibiotic drug candidate which demonstrated ... the development of sutezolid in combination with other TB ...
(Date:3/23/2017)... , Mar 23, 2017 Research and Markets ... & Trends - Industry Forecast to 2025" report to their ... The ... around 6.9% over the next decade to reach approximately $3.5 billion ... and forecasts for all the given segments on global as well ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... ... Walk with God #TruthwithGrace”: a devotional journal chronicling the writer’s path toward true ... How to Walk with God #TruthwithGrace” is the creation of published author Lea ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion ... real people of God in congregations across the United States. “The Communion ... ordained in 1964 who has served congregations in seven states throughout his long ...
(Date:3/23/2017)... Boulder, CO (PRWEB) , ... March 23, 2017 , ... ... higher bar for entry into teacher preparation programs. The NCTQ report suggests, based on ... boosting entry requirements would significantly improve teacher quality in the U.S. It argues that ...
(Date:3/23/2017)... New Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... a new clinic, located at 960 Gruene Road in Building 2. The clinic is ... co-owner Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings ...
(Date:3/23/2017)... Holland, PA and Grimsby, Ontario (PRWEB) , ... March 23, 2017 , ... The MBI ... the modular industry or whose acts have had a significant impact on the careers of ... Sales and Marketing with NRB Inc. was inducted into the MBI’s Hall of Fame. ...
Breaking Medicine News(10 mins):